Search
Upstream Bio Inc
UPBAdd to Watchlist
7.070USD
+0.160+2.32%
Close 08-14 16:00（ET）Quotes delayed by 15 min
387.23MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Upstream Bio Inc is 7.78, ranking 269 out of 387 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 75.00 and a low of 35.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
36.667
Target Price
+418.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Upstream Bio Inc
UPB
9
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Upstream Bio Inc's expected revenue for the next quarter?
Upstream Bio Inc's expected revenue is 472.29K.
What is Upstream Bio Inc's price target?
Analysts forecast that Upstream Bio Inc's price target is USD 43.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 35.00.
How have Upstream Bio IncUPB's recent earnings per share performed?
The market expectation was USD -0.73, while Upstream Bio IncUPB's earnings per share (EPS) for the previous quarter was USD -0.75. EPS for the next quarter is expected at USD -0.73.
What is the analyst rating for Upstream Bio Inc?
Based on the ratings of Upstream Bio Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.